See the latest industry league tables, and read exclusive industry analysis and C-suite interviews.
Ozempic debuts in India, priced in the ‘affordable zone’ for the country's population, with Novo Nordisk hoping the blockbuster drug can hold its own post impending loss of exclusivity in the country next year.
Ozempic debuts in India, priced in the ‘affordable zone’ for the country's population, with Novo Nordisk hoping the blockbuster drug can hold its own post impending loss of exclusivity in the country next year.
The drugmaker presented multiple posters of data for the recently reapproved BCMA-targeting antibody-drug conjugate at the just concluded ASH meeting.
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
The Switzerland-based group’s alpha-synuclein-targeted immunotherapy shows promise in slowing progression of the degenerative brain condition.
Having worked in stealth on its predictive computational R&D models, PsiThera has emerged to develop oral versions of blockbuster drug targets in inflammation and immunology.
This week, a focus on key results from the American Society of Hematology meeting: Jaypirca headed for the front line; Kite’s Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia’s early in vivo CAR-T data; and Novartis’s ianalumab’s potential in ITP.
The US FDA approved Uplizna (inebilizumab) for generalized myasthenia gravis, an increasingly crowded market. Amgen believes it can compete due to the CD19-targeting antibody’s durable efficacy with twice-yearly dosing.
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
The Switzerland-based group’s alpha-synuclein-targeted immunotherapy shows promise in slowing progression of the degenerative brain condition.
Recent moves in the industry include C-suite changes at Tyra Biosciences and HLB, plus seven companies get new CMOs and nine companies get new CFOs.
FOPO Edition: Capitalizing on positive data, eight drug developers priced follow-on public offerings that brought in $3.2bn, including $650m each for Terns and Structure plus $602m for Kymera.
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
The Watertown, MA-based biotech is set for a pivotal year, with multiple catalysts expected in 2026, including full data from a Phase II trial it previewed at ASH 2025.
